Skip to main content
. 2014 Jul 14;111(30):11127–11132. doi: 10.1073/pnas.1410432111

Fig. 3.

Fig. 3.

PTUPB inhibits primary tumor growth and metastasis. (A) PTUPB inhibits NDL breast tumor growth in FVB female mice (n = 6 mice per group). Experimental design (Upper Left), time course of NDL tumor growth (Lower Left), and representative images of mice on day 26 (Right). (B) PTUPB reduces CD31-positive endothelium in NDL tumors. (C) PTUPB reduces the circulating level of VEGF. (D) PTUPB inhibits LLC metastasis (n = 5–7 mice per group). PTUPB reduces lung tissue weight (Left) and suppresses LLC metastasis (Center); representative images of spontaneous lung metastasis are shown (Right). (Scale bar: 1 cm.) (E) PTUPB reduces the level of PGE2 in plasma in the NDL tumor experiments. n.s., not significant. (F) PTUPB increases levels of 11,12-EET and 14,15-EET in tumors. (G) PTUPB does not alter the ratio of PGI2 (stable metabolite 6-keto-PGF1α) to TXA2 (stable metabolite TXB2) in plasma. The results are expressed as mean ± SD. *P < 0.05; **P < 0.01; #P < 0.001.